SCHEMBL20535372

SCHEMBL20535372

NC(Cc1c(F)cc(C(=O)O)cc1F)=NO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPK1 P28482 2/20 0.39
HSD17B10 Q99714 2/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA7 P43166 2/20 0.39
CA9 Q16790 2/20 0.39
CA14 Q9ULX7 2/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
CA3 P07451 1/20 0.39
MAPT P10636 1/20 0.39
SELL P14151 1/20 0.39
HPGD P15428 1/20 0.39
SELP P16109 1/20 0.39
FUT4 P22083 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20535369 1.00 LMNA (0.39) LMNAKDM4EMAPK1HSD17B10CA12
SCHEMBL23294759 1.00 LMNA (0.39) LMNAKDM4EMAPK1HSD17B10CA12
SCHEMBL23316910 0.81 KDM4E (0.46) LMNAKDM4ECA12CA1CA2
SCHEMBL837173 0.80 LMNA (0.33) LMNAMAPTSMN1; SMN2KDM1ACYP1A2
SCHEMBL12246356 0.80 LMNA (0.33) LMNAMAPTSMN1; SMN2KDM1ACYP1A2
SCHEMBL837844 0.72 LMNA (0.41) LMNAALDH1A1TP53MAPTCA5A
SCHEMBL10263865 0.72 LMNA (0.41) LMNAALDH1A1TP53MAPTCA5A
SCHEMBL5053787 0.71 LMNA (0.44) LMNAKDM4EMAPK1HSD17B10CA12
SCHEMBL13304068 0.71 LMNA (0.44) LMNAKDM4EMAPK1HSD17B10CA12
SCHEMBL4129553 0.70 LMNA (0.44) LMNAKDM4EMAPK1HSD17B10CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110546140-B Selective HDAC6 inhibitors 意大发马克股份公司 2023-05-16 CN disclosed
EP-3562810-B1 BENZHYDROXAMIC ACID DERIVATIVES AS SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-05-03 EP disclosed
US-11351178-B2 Selective HDAC6 inhibitors ITALFARMACO SPA (IT) 2022-06-07 US disclosed
US-20210128577-A1 Selective HDAC6 Inhibitors ITALFARMACO S.P.A. (IT) 2021-05-06 US disclosed
CN-110546140-A selective HDAC6 inhibitors ITALFARMACO SPA 2019-12-06 CN disclosed
EP-3562810-A1 SELECTIVE HDAC6 INHIBITORS Italfarmaco SpA (IT) 2019-11-06 EP disclosed
WO-2018189340-A1 SELECTIVE HDAC6 INHIBITORS ITALFARMACO S.P.A. (IT) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210128577-A1 Selective HDAC6 Inhibitors HDAC6, HDAC1, HDAC3 LMNA 4062/4885KDM4E 308/4885MAPK1 1776/4885
US-11351178-B2 Selective HDAC6 inhibitors HDAC6, HDAC1, HDAC3 LMNA 4000/4885KDM4E 304/4885MAPK1 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.